Li C, Li W, Xiao J, Jiao S, Teng F, Xue S, et al. ADAP and SKAP55 deficiency suppresses PD-1 expression in CD8+ cytotoxic T lymphocytes for enhanced anti-tumor immunotherapy. EMBO Mol Med. 2015;7:754-69 pubmed publisher

Shirakawa K, Yan X, Shinmura K, Endo J, Kataoka M, Katsumata Y, et al. Obesity accelerates T cell senescence in murine visceral adipose tissue.. J Clin Invest. 2016;126:4626-4639 pubmed publisher

Imai Y, Ayithan N, Wu X, Yuan Y, Wang L, Hwang S. Cutting Edge: PD-1 Regulates Imiquimod-Induced Psoriasiform Dermatitis through Inhibition of IL-17A Expression by Innate γδ-Low T Cells. J Immunol. 2015;195:421-5 pubmed publisher

Sarraj B, Ye J, Akl A, Chen G, Wang J, Zhang Z, et al. Impaired selectin-dependent leukocyte recruitment induces T-cell exhaustion and prevents chronic allograft vasculopathy and rejection. Proc Natl Acad Sci U S A. 2014;111:12145-50 pubmed publisher

Verhagen J, Wraith D. Blockade of LFA-1 augments in vitro differentiation of antigen-induced Foxp3⁺ Treg cells. J Immunol Methods. 2014;414:58-64 pubmed publisher

Van der Jeught K, Joe P, Bialkowski L, Heirman C, Daszkiewicz L, Liechtenstein T, et al. Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity. Oncotarget. 2014;5:10100-13 pubmed

Park S, Namkoong H, Doh J, Choi J, Yang B, Park Y, et al. Negative role of inducible PD-1 on survival of activated dendritic cells. J Leukoc Biol. 2014;95:621-9 pubmed publisher

Liechtenstein T, Pérez-Janices N, Blanco-Luquin I, Goyvaerts C, Schwarze J, Dufait I, et al. Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy. Oncoimmunology. 2014;3:e945378 pubmed

Rabenstein H, Behrendt A, Ellwart J, Naumann R, Horsch M, Beckers J, et al. Differential kinetics of antigen dependency of CD4+ and CD8+ T cells. J Immunol. 2014;192:3507-17 pubmed publisher

Schwager K, Hemmerle T, Aebischer D, Neri D. The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. J Invest Dermatol. 2013;133:751-8 pubmed publisher

Noval Rivas M, Weatherly K, Hazzan M, Vokaer B, Dremier S, Gaudray F, et al. Reviving function in CD4+ T cells adapted to persistent systemic antigen. J Immunol. 2009;183:4284-91 pubmed publisher